Redeye comments on Camurus' Q3 report 2025, which was below our estimates due to a sequential sales decline of Buvidal sales in Europe. After the third quarter report, Camurus reported a strong phase I readout of CAM2056, the company's GLP-1 candidate.
LÄS MER